You are viewing Asia Pacific

CLOSTAT™

New Zealand

CLOSTAT™ contains a proprietary, patented strain of Bacillus subtilis, PB6. PB6 is a unique, naturally occurring spore-forming microorganism. Kemin identified and selected the specific strain of PB6 because it helps to maintain the balance of microflora in the intestinal tract of animal and livestock.

Features of CLOSTAT™

  • CLOSTAT™ Contains PB6, a unique strain of Bacillus subtilis
  • Stable during processing and packaging, when blended with other feed ingredients, and under normal commercial pelleting conditions
  • Easily mixed into animal diet to ensure that the proper dose is delivered through the feed

Benefits of CLOSTAT™

  • Proven efficacy in research studies
  • CLOSTAT™ provides consistent performance and value
  • Contributes to stable and healthy microflora in the intestinal

CLOSTAT™ IN SWINE

Stressors Affect Gut Health and Intestinal Intergrity

The intestinal tract of healthy swine contains a great number of different microorganisms whose balance promotes digestion, absorption of nutrients and overall health of the intestine. These microorganisms are both beneficial bacteria, such as Lactobacillus and Bifidobacterium spp, and pathogenic bacteria, such as Escherichia coli, Salmonella and Clostridium spp. Under normal circumstances, there is equilibrium between the bene cial and the pathogenic bacteria called eubiosis.

Sows are subjected to many stressors during their reproductive life cycle of breeding, gestation, farrowing and lactation. During these phases, different housing, management and feeding conditions affect the intestine micro ora balance. The result may be decreased maternal performance, reproductive efficiency and increased morbidity and mortality of nursing piglets.

KAA CLOSTAT PRODUCT PAGE IMAGES

Comparison of Sow Parameters

An improved maternal line of sows housed in a typical production unit were fed Bacillus subtilis (PB6) for 12 weeks. Production parameters on the farm were compared to the previous 12 week period where no Bacillus subtilis (PB6) was fed:

Item Previous 12 Weeks 12-week Trial Period
Non-productive sow days 57.50 54.40
Wean to 1st service (days)

6.36

6.51

Pre-Weaning mortality (%)

18.41

18.05

Pigs weaned/litter

9.63

9.75

Weaning weight/pig (lbs.)

12.84

12.92

Sow mortality (%)

9.52

9.05

Bacillus subtilis (PB6) fed to sows resulted in a 3 to 5 days improvement in non-productive sow days and a 0.36% reduction in pre-weaning mortality. Pigs nursing Bacillus subtilis (PB6) sows were heavier (12.92# versus 12.84#) and there were more of them (9.75 versus 9.63) at weaning. Sow mortality also decreased from 9.52% to 9.05%.

 

A Sow Lactation Trial Conducted in a Typical Production Unit

KAA CLOSTAT PRODUCT PAGE IMAGES
KAA CLOSTAT PRODUCT PAGE IMAGES

CLOSTAT™ IN POULTRY

Commercial Trial in Asia

CLOSTAT™ trial in replacing AGP in a commercial broiler was conducted in Asia.

Group Average Body Weight (kg) Feed Conversion Rate (FCR) Performance Index* (PI)
CLOSTAT™ 2.73 1.61 407
Enramycin 2.53 1.57 389

*Performance Index compare the live-bird performance of flocks which includes live weight, age, liveability and feed conversion efficiency.

KAA CLOSTAT PRODUCT PAGE IMAGES

 

CLOSTAT™ Highlights

CLOSTAT™ is compatible with common feed additives and most coccidiostats used in the feed industry and is heat stable under normal commercial pelleting conditions.

Exceptional customer service with best in class technical, laboratory and customer support from our dedicated teams and well-equipped laboratory.

  • Farm and facility audits to identify gut health issues
  • Feed and premix analysis to ensure recovery of CLOSTAT™
Variants Packaging Size Available (KG)
CLOSTAT™ 11 Dry 25
CLOSTAT™ SP Dry 5, 20
CLOSTAT™ 12 Dry 25

 

 

Certain statements may not be applicable in all geographical regions. Product labeling and associated claims may differ based upon government requirements. All claims are supported by scientific and field data.


Have a question about CLOSTAT™?